What Citanest Treats: Main Uses and Benefits

Citanest (Prilocaine) is considered relevant in situations where short-term pain prevention or relief is appropriate before a medical procedure. This medicine is commonly used to provide targeted localized analgesia that helps support various therapeutic interventions.

Citanest is applied to manage and ease anticipated pain in contexts such as routine dental procedures, minor surgical settings, and regional nerve block techniques. This use offers patients localized pain relief, contributing to a more manageable experience during certain therapeutic procedures.

“This medicine is relevant for easing acute procedural discomfort across dental, minor surgical, and complex regional contexts.”

Quick Fact: Relief for Procedural Pain Citanest assists in managing the acute, sharp discomfort associated with surgical or dental interventions, providing supportive relief when symptoms are more noticeable.

Regulatory References

1. Australian Government's NPS MedicineWise overview

Who Can and Cannot Use Citanest?

The official regulatory profile for Citanest (Prilocaine) establishes clear population eligibility constraints based on patient health status and age.

Populations Who Must Not Use Citanest (Contraindications)

Citanest is strictly contraindicated in patients with a known hypersensitivity to Prilocaine or any other amide-type local anesthetic. Use is also prohibited in patients diagnosed with congenital or idiopathic methemoglobinemia.

Eligibility Limitations and Restrictions

Eligibility is restricted based on age, physical status, and underlying health conditions:

• Age and Susceptibility: The medicine is not recommended for use in infants under six months of age due to an increased susceptibility to methemoglobinemia. Use in both children and older adults is permitted but is subject to eligibility rules related to physical status.
• Systemic Compromise: Use requires caution in patients with severe hepatic disease due to impaired metabolism, and in patients with impaired cardiovascular function (such as severe shock or heart block). Acutely ill or debilitated patients are also subject to eligibility restrictions.
• Pregnancy and Obstetrics: Safe use during human pregnancy has not been established. Citanest is not recommended for use in certain obstetric procedures, such as paracervical block.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Citanest (Prilocaine) around risks of additive toxicity and metabolic potentiation, not specific drug-drug contraindications. The medicine is, however, strictly contraindicated in patients with congenital or idiopathic methemoglobinemia due to the action of its metabolite, o-toluidine.

Co-administration with other local anesthetics or structurally related drugs, such as Class I Anti-arrhythmics (e.g., Mexiletine), may result in additive systemic toxic effects (cardiovascular and central nervous system). Increased monitoring is required when Prilocaine is used concurrently with Class III anti-arrhythmic drugs (e.g., Amiodarone), as cardiac effects may be compounded.

Pharmacodynamic Potentiation

Prilocaine's interaction risk is significantly increased when used with oxidizing agents or drugs known to induce methemoglobin formation. This class includes nitrates/nitrites (e.g., Nitroglycerin), sulfonamides, dapsone, and certain anticonvulsants (e.g., Phenytoin). This combination creates a documented risk of methemoglobinemia potentiation.

For specific populations, severe hepatic disease and renal dysfunction are noted in labeling as conditions that may impair Prilocaine's elimination, leading to an officially documented risk of toxic plasma concentrations. There are no mandatory timing requirements or documented, clinically significant interactions with food, alcohol, or herbal products specified in the injectable regulatory labels.

The mechanism of action of Prilocaine is defined by a sequence of molecular and physiological events that impose a reversible blockade on nerve impulse conduction. The core action is the non-selective blockade of voltage-gated sodium channels ( Na^+ channels) located in the membranes of peripheral nerve fibers. By physically obstructing these channels, the drug prevents the necessary rapid influx of sodium ions into the cell, thereby maintaining the polarized state of the membrane and preventing the electrical depolarization required for impulse generation.

This molecular intervention initiates a cascade in the nociceptive signaling pathway by inhibiting the generation of the action potential (electrical nerve impulse) along the axon. The resultant failure of impulse conduction leads directly to a functional failure of sensory nerve signal transmission, which results in a localized, reversible interruption of impulse conduction.

In certain combined formulations, a vasoconstrictor complements the anesthetic mechanism by activating local adrenergic receptors to cause blood vessel constriction. This secondary mechanism mechanically slows the rate at which Prilocaine is absorbed into the general circulation, thereby slowing the systemic removal of the anesthetic molecule from the nerve site.

How to Use Citanest (Prilocaine) — Administration Guidelines

Citanest (Prilocaine) is administered as a single dose for a defined procedure, adhering strictly to established usage guidelines. The medicine is primarily available as an Injectable Solution and in specialized Dental Cartridge form.

---

Routes and Dose Limitations

Prilocaine is used exclusively via parenteral injection into or near target tissues. Approved techniques include infiltration and various regional nerve blocks, such as the inferior alveolar block common in dentistry. In specific non-dental formulations, the medicine may also be used for epidural blocks.

For a healthy adult, the maximum total dose of Prilocaine must not exceed 600 mg (or 8 mg/kg) within a two-hour period, regardless of the technique employed. The administration is short-term and procedural, not scheduled for daily use.

---

Administration Conditions and Adjustments

Administration must follow specific procedural conditions described in labeling. The solution should be injected slowly, and the clinician must use frequent aspiration prior to and during the injection to prevent accidental entry into a blood vessel. Parenteral products must also be visually inspected for clarity before use.

Guidelines require dose reduction for specific patient populations to account for physiological changes. For elderly or debilitated patients, the dose must be reduced commensurate with their physical status. Similarly, a lower dosage is advised for patients with hepatic impairment, as Prilocaine is metabolized by the liver. Any remaining portion of a single-dose container must be discarded after the procedure.

Research evidence / Overview of studies for Citanest

---

Evidence for Local and Regional Nerve Blockade

The clinical evaluation of injectable Prilocaine has centered on its use in research settings involving regional and spinal blockades. Researchers primarily use Randomized Controlled Trials (RCTs) and systematic reviews to study this medicine. These studies examined technical aspects of nerve signal interruption, focusing on the time required for the start of the numbing effect (onset) and outcomes related to the duration of the blockade. These outcomes were explored in adult populations receiving nerve blocks for procedures such as dental and urological surgeries.

Findings describe patterns observed in the studies related to the duration of the nerve blockade. The reported success rates in specific nerve block applications was observed in some studies to be variable or mixed, and research notes the heterogeneity in the findings when compared to other local anesthetic compounds.

---

Evidence for Procedural Pain Prevention (Dermal and Mucosal Use)

Research has also examined Prilocaine for its use in providing numbness for dermal and mucosal procedures, such as those caused by minor invasive interventions. This evidence base relies on numerous systematic reviews and controlled trials. These studies explored patient-reported outcomes describing perceived discomfort and objective measures like changes in physiological strain.

Studies report measured changes in discomfort during procedures like starting an IV line or minor skin surgery. Research indicates that the measured effect is highly dependent on factors like the area of application and the application time. Additionally, subgroup findings are uncertain in some minor neonatal procedures (e.g., heel lancing), where studies reported no significantly measurable change in pain indicators.

---

Follow-up Duration, Long-Term Research, and Special Populations

The available research on Prilocaine primarily focuses on the acute, short-term activity evaluated in these procedural research settings. Consequently, long-term effects are not fully established in the scientific literature, as the clinical trials primarily focused on shorter-term observation periods.

Specific research has been studied for Prilocaine's use in children and neonates undergoing minor procedures. Conversely, data for certain groups remain insufficient, with limited information available from studies focusing on regional blocks in older adults (age 65 and above).

---

Key Evidence Gaps and Areas of Uncertainty

The primary gaps and uncertainties noted in the research include inconsistent comparative results across all specific regional nerve blocks, the lack of sufficient long-term data, and the variability in measured effects based on the conditions and methods under which the product was studied. Data for several special groups, including older adults, remains insufficient, meaning that results apply only to the populations studied in the primary trials.

Common questions about Citanest (FAQ)

---

Q: How long does the numbing effect of Citanest last after an injection?

According to official product information, the duration of the numbing effect may vary depending on the type of nerve block or infiltration technique used. For dental infiltration, the average soft tissue numbness is reported to last for approximately 2 to 2¼ hours. For an inferior alveolar nerve block, the average duration of soft tissue numbness is reported to be between 2½ to 3 hours.

---

Q: Is Citanest commonly used in dental procedures?

Yes, Prilocaine is specifically formulated and officially indicated for local anesthesia when used with infiltration and nerve block techniques in dental patients. This is one of its primary, confirmed uses according to regulatory labeling.

---

Q: Which side effects are considered Very Common with Prilocaine?

Regulatory documents classify side effects based on their frequency of occurrence. The undesirable effects officially listed as 'Very Common' (meaning they affect 1 in 10 or more patients) include low blood pressure (hypotension) and the feeling of being sick (nausea).

---

Q: What is the function of a vasoconstrictor when it is combined with Prilocaine?

A vasoconstrictor is added to some formulations to cause a localized narrowing of blood vessels. Regulatory information states that this action slows the rate at which Prilocaine is absorbed into the bloodstream, which is intended to keep the medicine concentrated at the site and may help to prolong the duration of the anesthetic effect.

---

Q: Are there any documented interactions between Citanest and alcohol or food?

Official regulatory labels generally do not list specific timing requirements or clinically significant drug interactions documented with food, alcohol, or herbal products. However, the label should be consulted for all known drug-to-drug interactions.

---

Q: How quickly does Citanest start working (onset of action)?

Official product information suggests a rapid action profile. When used for dental infiltration, the time for the onset of anesthesia is reported to average less than 2 minutes. For a nerve block, the time until the numbing effect begins is reported to average less than 3 minutes.

---

Q: Is Citanest available in a topical cream or gel form?

Prilocaine is the active ingredient in some combination topical anesthetic products, which are formulated as creams or gels. These products are often combined with lidocaine and are developed for application to the skin or mucous membranes.

---

Q: Does Prilocaine contain epinephrine?

The inclusion of epinephrine depends on the specific product name and formulation. Some brand-name formulations contain epinephrine as an added vasoconstrictor, while 'Citanest Plain' formulations are specifically prepared without this additive.

How to Store and Dispose of Citanest?

The storage and disposal of Citanest (prilocaine) must follow specific requirements defined by official regulatory bodies to maintain product stability and safety.

Official Storage Conditions

Constraint	Requirement
Temperature	Store at a temperature that does not exceed 25 C (77 F).
Protection	Keep the container protected from light and do not freeze the product.

Handling and Disposal Rules

Citanest is supplied in single-dose containers, and official labeling mandates that any unused portion remaining after a procedure must be safely discarded by the healthcare professional. This single-use requirement is essential for product quality. Disposal of the drug and its waste must always comply with all applicable national and local regulations.